CN105934254A - 作为哮喘肺中il-13活化的外周生物标志的二肽基肽酶-4（dpp4/cd26） - Google Patents

作为哮喘肺中il-13活化的外周生物标志的二肽基肽酶-4（dpp4/cd26） Download PDF

Info

Publication number
CN105934254A
CN105934254A CN201580005884.2A CN201580005884A CN105934254A CN 105934254 A CN105934254 A CN 105934254A CN 201580005884 A CN201580005884 A CN 201580005884A CN 105934254 A CN105934254 A CN 105934254A
Authority
CN
China
Prior art keywords
dpp4
patient
seq
level
asthma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580005884.2A
Other languages
English (en)
Chinese (zh)
Inventor
K.斯特雷彻尔
姚意弘
K.拉纳德
M.梁
I.维因什泰因
E.皮佩尔
R.梅
L.诺尔登马克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of CN105934254A publication Critical patent/CN105934254A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5437—IL-13
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/202—Dermatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
CN201580005884.2A 2014-01-27 2015-01-26 作为哮喘肺中il-13活化的外周生物标志的二肽基肽酶-4（dpp4/cd26） Pending CN105934254A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461931878P 2014-01-27 2014-01-27
US61/931878 2014-01-27
US201461990932P 2014-05-09 2014-05-09
US61/990932 2014-05-09
PCT/US2015/012885 WO2015112970A1 (en) 2014-01-27 2015-01-26 Dipeptidyl peptidase-4 (dpp4/cd26) as a peripheral biomarker of il-13 activation in asthmatic lung

Publications (1)

Publication Number Publication Date
CN105934254A true CN105934254A (zh) 2016-09-07

Family

ID=53682019

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580005884.2A Pending CN105934254A (zh) 2014-01-27 2015-01-26 作为哮喘肺中il-13活化的外周生物标志的二肽基肽酶-4（dpp4/cd26）

Country Status (12)

Country Link
US (1) US20160363591A1 (https=)
EP (2) EP3685857A1 (https=)
JP (1) JP2017509692A (https=)
KR (1) KR20160113700A (https=)
CN (1) CN105934254A (https=)
AU (1) AU2015209124A1 (https=)
BR (1) BR112016017192A2 (https=)
CA (1) CA2937387A1 (https=)
MX (1) MX2016009491A (https=)
RU (1) RU2016134838A (https=)
SG (1) SG11201606102UA (https=)
WO (1) WO2015112970A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109055522A (zh) * 2018-07-03 2018-12-21 吉林大学 C4orf38在制备用于检测或治疗神经性疼痛的产品中的应用
CN109715201A (zh) * 2016-09-23 2019-05-03 豪夫迈·罗氏有限公司 Il-13拮抗剂用于治疗特应性皮炎的用途
CN113155996A (zh) * 2021-03-23 2021-07-23 广州医科大学附属第一医院（广州呼吸中心） 15(s)-羟基二十碳四烯酸在评估变应原特异性免疫治疗效果中的应用
CN117554614A (zh) * 2022-09-23 2024-02-13 上海市第十人民医院 蛋白生物标志物dpp4在克罗恩病临床诊断中的应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1232290A1 (zh) * 2014-02-07 2018-01-05 Medimmune, Llc 检测人类骨膜蛋白的新型测定
AU2016205188A1 (en) 2015-01-09 2017-06-22 Medimmune, Llc Assay to detect human DPP-4
EP3371225A2 (en) * 2015-11-04 2018-09-12 AstraZeneca AB Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases
JP6871948B2 (ja) 2016-04-27 2021-05-19 アッヴィ・インコーポレイテッド 抗ｉｌ−１３抗体を使用する、ｉｌ−１３活性が有害である疾患の治療方法
CN113372446A (zh) 2016-06-08 2021-09-10 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
US10386368B2 (en) 2017-02-24 2019-08-20 Trustees Of Boston University Isolation of human lung progenitors derived from pluripotent stem cells
KR102330596B1 (ko) 2018-11-09 2021-11-26 아주대학교산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
EP4540284A2 (en) 2022-06-17 2025-04-23 Apogee Therapeutics, Inc. Antibodies that bind interleukin 13 and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101088089A (zh) * 2004-02-23 2007-12-12 鹿特丹伊拉斯姆斯大学医疗中心 通过基因表达图形对急性粒细胞性白血病进行分类、诊断和预后
CN102099485A (zh) * 2007-10-23 2011-06-15 临床基因组学有限公司 诊断新生物的方法-ⅱ
US20120052060A1 (en) * 2003-07-15 2012-03-01 Medimmune Limited Human Antibody Molecules For IL-13

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
WO2004104216A2 (en) * 2003-05-21 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
BRPI0720280A2 (pt) * 2006-12-11 2014-01-28 Wyeth Corp Métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13
US20090155784A1 (en) * 2007-01-22 2009-06-18 Wyeth Assessment of asthma and allergen-dependent gene expression
US20120005206A1 (en) * 2007-02-09 2012-01-05 Konstantinos Anagnostakis Apparatus and method for analysis of data traffic
BRPI0906261A2 (pt) 2008-03-31 2015-07-07 Genentech Inc "métodos de diagnóstico de um subtipo de asma em uma amostra de paciente, usos de um agente terapêutico e kits de diagnóstico de um subtipo de asma em uma amostra de paciente"
US20100221752A2 (en) 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
WO2012049278A1 (en) * 2010-10-15 2012-04-19 Medimmune Limited Therapies for improving pulmonary function
RU2578468C2 (ru) 2010-12-16 2016-03-27 Дженентек, Инк. Способы диагностики и лечения, связанные с ингибированием th2
WO2012158954A1 (en) 2011-05-18 2012-11-22 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120052060A1 (en) * 2003-07-15 2012-03-01 Medimmune Limited Human Antibody Molecules For IL-13
CN101088089A (zh) * 2004-02-23 2007-12-12 鹿特丹伊拉斯姆斯大学医疗中心 通过基因表达图形对急性粒细胞性白血病进行分类、诊断和预后
CN102099485A (zh) * 2007-10-23 2011-06-15 临床基因组学有限公司 诊断新生物的方法-ⅱ

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JONATHAN CORREN ET AL: "Lebrikizumab Treatment in Adults with Asthma", 《THE NEW ENGLAND JOURNAL OF MEDICINE》 *
MIYAGAKI, T ET AL: "Serum soluble CD26 levels: diagnostic efficiency for atopic dermatitis, cutaneous T-cell lymphoma and psoriasis in combination with serum thymus and activation-regulated chemokine levels", 《JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY》 *
SAMANTHA W M LUN ET AL: "Increased Expression of Plasma and CD4+ T Lymphocyte Costimulatory Molecule CD26 in Adult Patients with Allergic Asthma", 《JOURNAL OF CLINICAL IMMUNOLOGY》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109715201A (zh) * 2016-09-23 2019-05-03 豪夫迈·罗氏有限公司 Il-13拮抗剂用于治疗特应性皮炎的用途
CN109055522A (zh) * 2018-07-03 2018-12-21 吉林大学 C4orf38在制备用于检测或治疗神经性疼痛的产品中的应用
CN113155996A (zh) * 2021-03-23 2021-07-23 广州医科大学附属第一医院（广州呼吸中心） 15(s)-羟基二十碳四烯酸在评估变应原特异性免疫治疗效果中的应用
CN117554614A (zh) * 2022-09-23 2024-02-13 上海市第十人民医院 蛋白生物标志物dpp4在克罗恩病临床诊断中的应用

Also Published As

Publication number Publication date
EP3099323A4 (en) 2017-10-04
MX2016009491A (es) 2017-01-13
AU2015209124A1 (en) 2016-08-18
JP2017509692A (ja) 2017-04-06
KR20160113700A (ko) 2016-09-30
RU2016134838A (ru) 2018-03-07
BR112016017192A2 (pt) 2017-10-10
US20160363591A1 (en) 2016-12-15
RU2016134838A3 (https=) 2018-09-27
EP3685857A1 (en) 2020-07-29
SG11201606102UA (en) 2016-08-30
EP3099323A1 (en) 2016-12-07
CA2937387A1 (en) 2015-07-30
WO2015112970A1 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
CN105934254A (zh) 作为哮喘肺中il-13活化的外周生物标志的二肽基肽酶-4（dpp4/cd26）
Papadopoulou et al. Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care
McDowell et al. Exacerbation profile and risk factors in a type-2–low enriched severe asthma cohort: a clinical trial to assess asthma exacerbation phenotypes
Westhoff et al. Fatigue and depression predict physician visits and work disability in women with primary Sjögren’s syndrome: results from a cohort study
US11016099B2 (en) Prediction of clinical response to IL23-antagonists using IL23 pathway biomarkers
Mohan et al. Questions in mild asthma: an official American Thoracic Society research statement
AU2016349113A1 (en) Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases
US20220144935A1 (en) Ccl20 as a predictor of clinical response to il23-antagonists
Crimi et al. Type 2-high severe asthma with and without bronchiectasis: a prospective observational multicentre study
Domingo et al. Association of circulating biomarkers with illness severity measures differentiates myalgic encephalomyelitis/chronic fatigue syndrome and post-COVID-19 condition: a prospective pilot cohort study
Sen et al. Flares in IIMs and the timeline following COVID-19 vaccination: a combined analysis of the COVAD-1 and-2 surveys
Reihman et al. Management of severe asthma beyond the guidelines
RU2383019C1 (ru) Способ прогнозирования риска развития бронхиальной астмы
Alexeeva et al. Comparative analysis of the etanercept efficacy in children with juvenile idiopathic arthritis under the age of 4 years and children of older age groups using the propensity score matching method
Provan et al. Interstitial lung disease in rheumatoid or psoriatic arthritis patients initiating biologics, and controls-data from five Nordic registries
Dahmani et al. The C-589T IL-4 single nucleotide polymorphism as a genetic factor for atopic asthma, eczema and allergic rhinitis in an eastern Algerian population
Watchorn et al. Investigational approaches for unmet need in severe asthma
Ford et al. GRAPPA Trainees Symposium 2018: a report from the GRAPPA 2018 annual meeting
Al-Benna Toxic epidermal necrolysis syndrome: management and outcomes
Venge Blood Eosinophils to Direct Corticosteroid Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease
Zeineddine Long-term safety and efficacy of high efficacy disease-modifying therapies in multiple sclerosis patients
Harries downloaded from the King’s Research Portal at https://kclpure. kcl. ac. uk/portal
Zou et al. Specific IgE response to fungi and asthma severity
Al Zahrani Defining the relationship between clinical and immunological features of asthma
Soares Effect of Genetic Variation on Healthcare Outcomes in Children and Adults with Eczema and Asthma

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160907

WD01 Invention patent application deemed withdrawn after publication